HIV-1-infection
Conditions
Brief summary
The authors hypothesize that there is a correlation between the percentage of CD4+ T cells expressing CD32a and/or X and the quantity of DNA found in peripheral blood mononuclear cells in patients infected with HIV-1. Also, that there is a correlation between expression of CD32a and/or X and proviral load.
Interventions
OTHERBioclinical evaluation
50-100ml blood extracted for flow cytometry and qPCR
Sponsors
Institut de Génétique Moléculaire de Montpellier
Centre Hospitalier Universitaire de Nīmes
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patient infected with aviremic HIV-1 (\<20 copies of HIV-1 RNA/ml plasma) undergoing antiretroviral treatment for at least 2 years * Patient has known duration of infection and treatment * Patient has known pretherapeutic CD4+ T cell count and viremia * Patient has known CD4+ T cell count, residual viremia and CD4/CD8 ratio for previous 2 years * Patient weighs at least 56kg * The patient is not opposed to their inclusion in the study * The patient must be a member or beneficiary of a health insurance plan * Patient at least 18 years old
Exclusion criteria
* Patient has an acute infection * The subject has already been included in the study or is in a period of exclusion determined by a previous study * It is impossible to give the subject informed information * The patient is under safeguard of justice or state guardianship * Patient is pregnant, parturient or breastfeeding
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of CD4+ T cells expressing CD32 alone | Day 0 | % |
| Percentage of CD4+ T cells expressing X alone | Day 0 | % |
| Percentage of CD4+ T cells expressing both CD32 and X | Day 0 | % |
| Quantification of proviral load | Day 0 | Quantitative PCR; number of copies of HIV-1 DNA per million peripheral blood mononuclear cells |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Pre-therapeutic viremia | Day 0 | Number of copies of HIV-1 RNA/ml plasma |
| Change in CD4+ T cells over previous 2 years | Day 0 | Number of CD4+ T cells/microL blood lost per year |
| Change in CD4+ T cells prior to treatment | Day 0 | Number of CD4+ T cells/microL blood lost per year |
| Change in CD4+ T cells during treatment | Day 0 | Number of CD4+ T cells/microL blood lost per year |
| Viremia at inclusion into the study | Day 0 | Number of copies of HIV-1 RNA/ml plasma |
| Viremia during the 2 previous years | Day 0 | Number of copies of HIV-1 RNA/ml plasma |
| Residual immune activation at inclusion into the study | Day 0 | CD4/CD8 ratio |
| Duration of infection prior to treatment | Day 0 | Months |
| Nature of current treatment | Day 0 | Family of molecule |
| Co-infection with hepatitis C virus | Day 0 | Yes/No |
| Co-infection with hepatitis B virus | Day 0 | Yes/No |
| Co-infection with Cytomegalovirus | Day 0 | Yes/No |
| Co-infection with Epstein-Barr virus | Day 0 | Yes/No |
| Testing for intact proviral DNA | Day 0 | Number of copies/million cells |
| Circulating viral RNA sequence | Day 0 | RNA sequence |
| Residual immune activation during the previous 2 years | Day 0 | CD4/CD8 ratio |
| Duration of treatment | Day 0 | Months |
| Year treatment commenced | Day 0 | Year |
| Pre-therapeutic CD4 + T cell count | Day 0 | Number of CD4+ T cells/ microL blood |
Countries
France
Outcome results
None listed